How, if at all, do you anticipate incorporating Pixclara PET into the evaluation of suspected recurrent or progressive glioma after treatment?

In pediatric high-grade glioma, I think there's an opportunity to use it selectively when conventional MRI leaves uncertainty between true progression and treatment-related change (pseudoprogression), rather than as part of routine surveillance. The clearest need is in diffuse midline glioma after r...

I anticipate two major ways to employ Amino acid (or FET) PET:

1. Following the EANO consensus guidelines on radiation necrosis, these studies will provide complementary information to perfusion MRI when evaluating treatment effects vs true disease progression [Duernick et al., PMID 42423280].
2. Since we...